Literature DB >> 1867420

Neuromuscular effects of succinylcholine on the vocal cords and adductor pollicis muscles.

C Meistelman1, B Plaud, F Donati.   

Abstract

To quantify the effects of succinylcholine at the laryngeal adductor muscles and the adductor pollicis, 17 adult patients were studied during propofol-fentanyl anesthesia. Train-of-four stimulation was applied to the ulnar nerve at the wrist and the recurrent laryngeal nerve at the notch of the thyroid cartilage. Laryngeal response was measured as pressure changes in the cuff of the tracheal tube positioned between the vocal cords. The force of contraction of the laryngeal adductor muscles and of the adductor pollicis were compared after administration of 0.25 or 0.5 mg/kg of succinylcholine. With 0.25 mg/kg, maximum blockade of first twitch (T1) was 66% +/- 10% (mean +/- SEM) and 45% +/- 13% at the vocal cords and the adductor pollicis, respectively (P less than 0.01). After 0.5 mg/kg, maximum blockade at the vocal cords (93% +/- 2%) and the adductor pollicis (84% +/- 6%) did not differ significantly. For both doses, time to maximal blockade was shorter for the vocal cords (0.9 +/- 0.1 min) than for the adductor pollicis (1.7 +/- 0.2 min; P less than 0.01). Time to 90% recovery of T1 after a bolus of 0.5 mg/kg was similar at the vocal cords (4.3 +/- 0.5 min) and the adductor pollicis (5.2 +/- 0.8 min) (NS). The ED50 was less at the laryngeal adductors (0.170 mg/kg) than at the adductor pollicis (0.278 mg/kg). It is concluded that, in adults, succinylcholine-induced blockade is more rapid and more intense at the laryngeal muscles than at the adductor pollicis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867420     DOI: 10.1213/00000539-199109000-00009

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

1.  Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.

Authors:  C Ibebunjo; C B Srikant; F Donati
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

Review 2.  Pharmacokinetics and pharmacodynamics of rapacuronium bromide.

Authors:  William J Wight; Peter M C Wright
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  How much relaxation?

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

4.  Different priming techniques, including mivacurium, accelerate the onset of rocuronium.

Authors:  M Naguib
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

5.  Does monitoring of post-tetanic count prevent alarms of airway pressure or visible muscle activity during intratracheal jet ventilation? A prospective study with five different neuromuscular blocking agents.

Authors:  A I Puura; M G Rorarius; P Laippala; G A Baer
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

6.  Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans.

Authors:  C Meistelman; B Plaud; F Donati
Journal:  Can J Anaesth       Date:  1992-09       Impact factor: 5.063

7.  Pharmacodynamic behaviour of rocuronium in the elderly.

Authors:  D R Bevan; P Fiset; P Balendran; J C Law-Min; A Ratcliffe; F Donati
Journal:  Can J Anaesth       Date:  1993-02       Impact factor: 5.063

8.  Succinylcholine and vecuronium blockade of the diaphragm, laryngeal and limb muscles in the anaesthetized goat.

Authors:  C Ibebunjo; L W Hall
Journal:  Can J Anaesth       Date:  1994-01       Impact factor: 5.063

9.  Comparison of intubating conditions of rocuronium bromide and vecuronium bromide with succinylcholine using "timing principle".

Authors:  Veena Chatrath; Iqbal Singh; Raman Chatrath; Neha Arora
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2010-10

Review 10.  Monitoring of neuromuscular function in the clinical setting.

Authors:  D Kelly; S J Brull
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.